GlassScriptPhysician profile
Bac Nguyen
NPI 1871853077
$318,933.51
in general payments reported to CMS, 2019-2025
29 companies · $52K in 2025
The $52K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $20K · 2021: $27K · 2022: $84K · 2023: $59K · 2024: $57K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Consulting Fee: $39K · Food and Beverage: $23K · Honoraria: $21K · Travel and Lodging: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,838 · Entertainment: $217 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,820.00 |
| Consulting Fee | $39,362.60 |
| Food and Beverage | $23,010.32 |
| Honoraria | $21,125.60 |
| Travel and Lodging | $10,605.87 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,837.50 |
| Entertainment | $217.31 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $67,548.09 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Abbvie INC. | $64,645.47 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $41,015.91 | 2019-2021 | |
| Allergan, INC. | $40,308.40 | 2019-2022 | |
| New World Medical,INC. | $40,003.42 | 2019-2025 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Glaukos Corporation | $34,880.36 | 2019-2025 | Idose, Travoprost Intraocular Implant - Idose, Idosetr |
| Bausch & Lomb Americas INC. | $10,811.06 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $8,996.95 | 2019-2021 | |
| Dompe US, INC. | $1,860.13 | 2023-2024 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $1,847.93 | 2019-2023 | Tecnis Iol |
| Ivantis, INC | $1,811.56 | 2019-2021 | |
| Iridex Corporation | $1,177.81 | 2019-2022 | |
| Optos, INC. | $803.46 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $651.31 | 2024-2025 | Xdemvy |
| Alcon Research LLC | $570.00 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $388.98 | 2019-2024 | Omni Surgical System |
| Nova Eye, INC. | $375.33 | 2024-2025 | |
| Beaver-Visitec International, INC. | $281.47 | 2019-2025 | |
| Carl Zeiss Meditec, INC. | $209.91 | 2022 | |
| Oyster Point Pharma, INC. | $179.12 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $161.92 | 2019-2023 | |
| Alimera Sciences, INC. | $112.65 | 2019 | |
| Bausch Health US, LLC | $102.52 | 2019 | |
| Thea Pharma INC. | $53.03 | 2024-2025 | Iyuzeh |
| Regeneron Healthcare Solutions, INC. | $39.11 | 2022 | |
| Harrow Eye, LLC | $31.76 | 2025 | Triesence |
| Medtronic, INC. | $28.98 | 2025 | Valleylab Ft10 |
| Biotissue Holdings INC. | $23.28 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.59 | 2024 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bac Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.